Health

  • November 13, 2025

    2nd Circ. Upholds NY's Ban On Selling Diet Pills To Minors

    The Second Circuit on Thursday rejected a trade group's bid to block a New York law that bars companies from selling weight loss and muscle-building supplements to minors, finding the group likely won't win its First Amendment challenges and retailers' "speculative predictions" of lost sales aren't enough to show irreparable harm.

  • November 13, 2025

    2nd Circ. Revives Bright Health Investors' Pandemic Suit

    The Second Circuit on Thursday revived a suit alleging healthcare management services company Bright Health Group Inc. misled investors in its 2021 initial public offering about its anticipated costs during the COVID-19 pandemic, finding that the complaint plausibly alleged the defendants hid preexisting operational issues and risks.

  • November 13, 2025

    Fla. Hospitals Didn't Prove Opioid Conspiracy, Jurors Told

    Walgreens told a state court jury on Thursday that Florida hospitals haven't proven that the company conspired with Walmart, CVS and pharmaceutical manufacturers to illegally dispense opioids through their pharmacies, arguing that the corporations shouldn't be liable for $1.5 billion in damages for contributing to an epidemic of opioid-addicted patients. 

  • November 13, 2025

    Hemp Policy At Crossroads After Government Reopening Bill

    Hemp industry advocates are pledging to use the one-year gap between enactment and implementation of the government funding agreement, which effectively recriminalized most hemp-derived THC products, to craft new regulatory legislation that stops short of a full ban.

  • November 13, 2025

    NC Biz Court Bulletin: Rulings Spotlight Coverage Clashes

    The North Carolina Business Court plowed into the fourth quarter with two big decisions in insurance disputes that involved $50 million in COVID-19-related losses at a chain of outlet malls, and an industrial accident at a Nucor Corp. iron plant in Louisiana.

  • November 13, 2025

    CVS Reaches Deal In 'Non-Drowsy' Labeling Class Action

    A woman has agreed to settle her proposed class action against CVS Pharmacy accusing it of deceptively marketing its flu medicine as "non-drowsy" when it contained a drug known to cause drowsiness.

  • November 13, 2025

    Texas Court Says Landowner Doesn't Have To Sell $22M Plot

    A Texas Business Court judge ruled that a landowner doesn't have to go forward with a previously planned $22.5 million sale of 20.8 acres of land because the buyer terminated the deal.

  • November 13, 2025

    Donor Info Subpoena Chills Speech, Anti-Abortion Org Says

    An organization that operates anti-abortion pregnancy centers told the U.S. Supreme Court on Thursday that New Jersey is undermining its own subpoena power in a bid to avoid constitutional review of its request for information about the group's donors.

  • November 13, 2025

    Weight-Loss Drug MDL In Pa. Grows With 3 New Jersey Cases

    Three New Jersey cases were grouped into multidistrict litigation accusing Eli Lilly & Co. and Novo Nordisk of downplaying alleged side effects of weight loss drugs like Ozempic and Trulicity, according to a transfer order filed in Pennsylvania federal court.

  • November 13, 2025

    Maya Kowalski Fights Fla. Appeals Court's $213M Reversal

    The subject of the Netflix documentary "Take Care of Maya" has asked a Florida appeals court to reconsider its decision reversing a $213 million judgment, saying the court needs to clarify how far the immunity that state law grants to those who report possible child abuse extends.

  • November 13, 2025

    Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal

    Pediatric cancer-focused biopharmaceutical company Day One Biopharmaceuticals, led by Fenwick & West LLP, announced plans Thursday to acquire clinical-stage biopharmaceutical company Mersana Therapeutics Inc., advised by WilmerHale, in a take-private deal worth up to $285 million.

  • November 13, 2025

    FTC Fails To Block Doctors' Testimony In $945M Merger Case

    A D.C. federal judge refused Thursday to bar a pair of outside doctors and consultants from vouching for Edwards Lifesciences Corp.'s planned JenaValve Technology Inc. acquisition, preferring to let the Federal Trade Commission contest their testimony in cross-examination and saying from the bench that he'll "make some popcorn."

  • November 13, 2025

    MVP: Foley & Lardner's Jason Mehta

    Jason Mehta, co-chair of Foley & Lardner LLP's healthcare litigation team, helped secure a bombshell ruling declaring parts of the False Claims Act unconstitutional and successfully defended COVID-19 test kit providers facing government investigations, earning him a spot as one of the 2025 Law360 Healthcare MVPs.

  • November 13, 2025

    Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL

    A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.

  • November 13, 2025

    DocGo Investors Seek OK Of $12.5M Deal Over Ex-CEO Claims

    Investors of mobile medical provider DocGo have asked a New York federal court to grant preliminary approval of their $12.5 million settlement of claims that the company deceived stockholders before a $432 million contract with New York City to provide emergency migrant housing came under public scrutiny.

  • November 13, 2025

    Virtua, Trinity Health Reach Deal Over $12M Legal Bill

    Virtua Health Inc. has reached a deal to settle its claims that Trinity Health Corp. backed out of an agreement to cover $12 million in counsel fees and costs incurred in a legal fight with a rival healthcare system, according to a New Jersey federal court order dismissing the suit with prejudice.

  • November 12, 2025

    Valsartan Cancer Expert Blocked, Ending First Injury Trial

    What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.

  • November 12, 2025

    Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC

    Sandoz Inc. and its marketing firm RareGen LLC urged a Third Circuit panel on Wednesday to reinstate the full $137.2 million awarded in breach of contract damages against United Therapeutics Corp., claiming a lower court's decision to halve the damages provided a windfall to their adversary.

  • November 12, 2025

    NJ Justices Keep Ozempic Injury Mass Torts Separate

    The New Jersey Supreme Court has decided not to combine two Bergen County Superior Court mass tort cases over weight loss drugs including Ozempic, Wegovy and Mounjaro, keeping them separate based on the type of injury alleged.

  • November 12, 2025

    Judge Confirms $620K Award In Radiology Contract Dispute

    A Georgia federal judge on Wednesday upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, rejecting the latter's bid to vacate the decision by claiming an arbitrator misinterpreted their long-standing services agreement.

  • November 12, 2025

    Fla. Lacked Evidence For Psychiatric Hold, Court Says

    A Florida appeals court on Wednesday reversed an involuntary commitment order after the state conceded its evidence was insufficient for a finding of mental illness under state law.

  • November 12, 2025

    1st Circ. Weighs Federal Halt To Planned Parenthood Funding

    First Circuit judges skeptically questioned a Planned Parenthood attorney Wednesday as they wrestled with whether Congress illegally singled out the organization in budget legislation that blocks its federal Medicaid funding for a year.

  • November 12, 2025

    Providence Health Nears ERISA Deal Over 401(k) Admin Costs

    Providence Health & Services has reached a tentative deal to resolve a proposed class action accusing the nonprofit healthcare system of misspending millions of dollars in forfeited employer retirement contributions in violation of federal benefits law, the parties told a Seattle federal judge.

  • November 12, 2025

    Judge Questions Cigna Site Users' Standing In Data Suit

    A Pennsylvania federal judge suggested Wednesday that she may toss a proposed class action alleging Cigna failed to safeguard private health data by tracking plan members' website usage in violation of state wiretapping and federal privacy laws, ordering the plaintiffs to demonstrate that they have standing to sue.

  • November 12, 2025

    MVP: Bass Berry's Michael Hess

    Michael Hess of Bass Berry & Sims PLC represented private equity firm Sycamore Partners in its roughly $24 billion deal taking Walgreens off the public market, earning him a spot among the 2025 Law360 Healthcare MVPs.

Expert Analysis

  • How To Prep For Potential Passage Of SAFER Banking Act

    Author Photo

    The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.

  • The Future Of Lab-Test Regs After FDA Rescinds Rule

    Author Photo

    The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.

  • What 2 Profs Noticed As Transactional Law Students Used AI

    Author Photo

    After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.

  • Rebuttal

    BigLaw Settlements Should Not Spur Ethics Deregulation

    Author Photo

    A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.

  • Opinion

    8th Circ. Should Reaffirm False Commercial Speech's Nature

    Author Photo

    The Eighth Circuit in Goldfinch Laboratory v. Iowa Pathology Associates should assert that false commercial speech is not categorically immune from antitrust scrutiny, says Daniel Graulich at the Federal Trade Commission.

  • Unpacking Ore. Law's Limits On PE Healthcare Investment

    Author Photo

    A recent Oregon law imposes significant restrictions on nonphysicians owning or controlling medical practices, but newly enacted amendments provide some additional flexibility in certain ownership arrangements without scuttling the law's intent of addressing concerns about the rise of private equity investment in healthcare, say attorneys at Debevoise.

  • 5 Ways Lawyers Can Earn Back The Public's Trust

    Author Photo

    Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.

  • Criminal Healthcare Fraud Takeaways From 4th Circ. Reversal

    Author Photo

    After the Fourth Circuit reversed a doctor’s postconviction acquittal in U.S. v. Elfenbein last month, defense attorneys should consider three strategies when handling complex criminal healthcare matters, says Jonathan Porter at Husch Blackwell.

  • Opinion

    Furtive Changes To Federal Health Data Threaten Admissibility

    Author Photo

    A recent study showing that nearly 100 U.S. federal health datasets have been modified this year without any notation in official change logs should concern plaintiffs counsel, defense counsel and judges alike — because undermining data's integrity, authenticity and chain of custody threatens its admissibility in litigation, say attorneys at Kershaw Talley.

  • Series

    Hiking Makes Me A Better Lawyer

    Author Photo

    On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.

  • What US-India Trade Deal Will Mean For Indian Pharma

    Author Photo

    Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.

  • Series

    Law School's Missed Lessons: Negotiation Skills

    Author Photo

    I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.

  • Conflicting Developments In Homelessness Legal Landscape

    Author Photo

    Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.